Loading...
Market
In which major medical journal will Neuralink's Blindsight be featured by December 31, 2025?
2
Resolution / Starting Odds
The Lancet • 25%
New England Journal of Medicine • 25%
JAMA • 25%
Other • 25%
Medical journal publications, Neuralink announcements
Story
Neuralink's Blindsight Receives FDA Breakthrough Device Designation on September 17, 2024
Sep 17, 2024, 07:12 PM
Neuralink, the brain-chip startup founded by Elon Musk, has received the U.S. Food and Drug Administration's (FDA) Breakthrough Device Designation for its brain implant chip named Blindsight on September 17, 2024. This designation is given when preliminary clinical evidence suggests that the device may offer substantial improvement over existing treatments. Blindsight aims to restore vision in individuals who were born blind or have lost their eyesight, including those without optic nerves, provided their visual cortex is intact. The device has already demonstrated success in monkeys and allows patients to control a mouse using only their thoughts. Blindsight is Neuralink's next product after Telepathy.
View original story
Similar markets
Significant improvement in vision • 25%
Moderate improvement in vision • 25%
No noticeable improvement • 25%
Negative side effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Infrared vision capability • 25%
Ultraviolet vision capability • 25%
Both infrared and ultraviolet vision capabilities • 25%
Neither capability • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Restoring eyesight to a blind individual • 25%
Enhancing vision for partially sighted individuals • 25%
Other medical applications • 25%
No application by end of 2024 • 25%
Google • 25%
Apple • 25%
Microsoft • 25%
Other • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%